Latest news with #Keros
Yahoo
29-05-2025
- Business
- Yahoo
Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45%
Keros Therapeutics Inc (NASDAQ:KROS) released topline data from the TROPOS Phase 2 trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension (PAH) on Wednesday. In December 2024, the company voluntarily halted the 3.0 mg/kg and 4.5 mg/kg treatment arms based on observing pericardial effusions at those dose levels. Furthermore, in January 2025, the company halted all dosing in the trial, including the 1.5 mg/kg and placebo treatment arms, based on the ongoing safety review due to new observations of pericardial effusion adverse the early termination of the trial, patients continued to be monitored through their end-of-trial visits. Following the analysis of all available safety and efficacy data from the TROPOS trial, the company has decided to discontinue all development of cibotercept in PAH. In a corporate presentation, the company noted a higher incidence in cibotercept arms relative to placebo and a higher incidence rate and severity in the 3.0 and 4.5 mg/kg arms than the 1.5 mg/kg arm. The background rate of pericardial effusions in this trial was higher than in randomized, controlled trials of Merck & Company, Inc.'s (NYSE:MRK) Winrevair (sotatercept). Keros said the ability to interpret 24-week data is limited due to incomplete treatment duration and trial visit participation. A dose-dependent signal for pericardial effusions was observed for cibotercept in this PAH population. During the treatment duration in the analysis from this data cutoff, no major signal for hemoglobin increases, thrombocytopenia, bleeding events, or telangiectasias was observed relative to the placebo. No clinically meaningful improvement in pulmonary vascular resistance (PVR) or 6-minute walk distance (6MWD) was observed. The company plans to further evaluate the appropriate development strategy for cibotercept, if any, in other indications following the completion of the strategic alternative review process. Keros has decided to reduce the company's headcount by approximately 45%, after which the company will have 85 full-time employees. The company expects to realize average annualized cost savings of approximately $17 million. Price Action: KROS stock is trading lower by 4.78% to $13.94 at last check Thursday. Read Next:Image via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45% originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28-05-2025
- Business
- Yahoo
Detroit Grand Prix: Downtown businesses cashing in during busy event week
The Brief The Movement Festival has wrapped, and now Detroit will be extra busy with the Grand Prix. Restaurants and other businesses tell FOX 2 they have been appreciating the extra foot traffic. The Detroit Grand Prix begins Friday, May 30. DETROIT (FOX 2) - It has been a busy week for the Motor City after thousands of people were downtown for the Movement Festival, and now thousands are expected for the Detroit Grand Prix. Meanwhile, restaurants and other businesses tell FOX 2 they have been appreciating the extra foot traffic. What they're saying Jenna Bruski and Danny Moreno, two people from Chicago, were among the thousands this weekend at the Movement Festival in downtown Detroit. But before they hit the road on Tuesday, they stopped by American Coney Island. Owner Grace Keros was happy to have them and all who dined there during the event. "Movement was really good for us. Anytime there's a big event downtown," Keros said. "It's good for not only myself but for all businesses." She says they saw a spike in sales while selling tons of hotdogs, wings, and water. "Very much increased foot traffic, even late into the evening, which is good," Keros said. "Another thing I appreciated because sometimes crowds get a little unruly or rowdy, I should say. These were great, great people. Great crowd. A lot of fun." Manager of Locos Tex-Mex, Alexis Odom, said they were not prepared for such a large turnout, but they're grateful and always love it when the Grand Prix comes to town. She says they too saw a bump in sales. "Yeah, at least, at least about 40% to 50% of an increase on the days that they are here," Odom said. What's next Now businesses are already preparing for the Grand Prix coming this weekend, and they believe it will be a huge success. "Just everything that has been going on for the last couple of years, I'm very proud of Detroit. And I'm happy. So, like, welcome. Bring everything back here, okay," Odom said. The Grand Prix begins on Friday, May 30. Just know there is tons of construction in the downtown area, so plan ahead before you travel.
Yahoo
27-05-2025
- Business
- Yahoo
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote 'FOR' All of Keros' Director Nominees
Keros Board Best Equipped to Oversee Strategic Review Process and Execute on Ultimate Outcome of that Process ADAR1's Disruptive and Self-Serving Campaign Stands to Jeopardize the Future Value Maximizing Potential of the Company Keros Urges Stockholders to Protect the Value of Their Investment by Voting 'FOR' All Three of the Company's Highly Qualified Director Nominees LEXINGTON, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ('Keros', the 'Company' or 'we') (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ('TGF-ß') family of proteins, today announced that leading independent proxy advisory firm Glass Lewis & Co. ('Glass Lewis') recommended that Keros stockholders vote 'FOR' all three of the Company's highly qualified director nominees in connection with its Annual Meeting of Stockholders (the 'Annual Meeting') scheduled for June 4, 2025. Keros issued the following statement in connection with Glass Lewis' report: We are pleased that Glass Lewis recognizes the value that our directors bring to the Board and understands that the Board and management team's actions taken to date to maximize stockholder value are reasonable and measured. Our Board is intentionally built, comprised of experienced individuals, many of whom directly represent stockholders, and will continue to focus on evaluating alternatives in the best interests of the Company and all stockholders. We continue to believe that the most constructive course of action for stockholders at this pivotal stage in our strategic alternatives review is to remain focused on effectively running the company and a comprehensive process rather than being sidetracked by a self-serving and value-destructive campaign. Glass Lewis stated in its May 27, 2025 report1: 'On the other hand, we note that the magnitude of the Company's share price collapse appears to stem primarily from inherent clinical development risk rather than board-level mismanagement. In particular, the setback in the TROPOS clinical trial – and the subsequent 73% one-day share price decline – reflects the volatile and often binary nature of clinical-stage biotech investing, especially in cases where a company's valuation is heavily reliant on a lead product candidate that has not yet been clinically de-risked. To date, and to the best of our knowledge, no credible evidence has emerged to suggest the board mismanaged the trial or disregarded known safety signals.' 'ADAR1 has not presented compelling evidence that either directors Gray or Seth played a disproportionate role in the Company's missteps or failed to fulfill their core duties as independent directors. In the absence of such evidence – and considering the board's recent initiation of a strategic review process and its continued willingness to engage with shareholders – we do not believe there is a sufficiently strong accountability rationale to warrant withholding support from either nominee at this time.' 'Although ADAR1's arguments for increased capital discipline may resonate with shareholders, we believe the board's decision to retain flexibility through a formal strategic review – led by a special committee of independent, disinterested directors – represents a reasonable and measured approach at this time. While a substantial capital return may ultimately be warranted, we believe this is better determined in the context of a completed and comprehensive evaluation of strategic alternatives.' 'While ADAR1 has characterized the Rights Plan as an entrenchment device, the plan's adoption appears to us to be reasonably timed and narrowly scoped, and does not reflect the more aggressive features often seen in contested situations.' 'Although shareholder rights plans are generally viewed with caution by investors and Glass Lewis, particularly in the context of public shareholder dissent, the facts of this case do not, in our view, suggest that the board acted in bad faith or sought to preempt legitimate shareholder participation.' 'In our view, the board's recent initiation of a strategic review, led by an independent special committee, represents a constructive step in addressing shareholder concerns.' Keros issued the following statement in response to ADAR1 Capital Management, LLC ('ADAR1')'s misleading claims: In a recent press release, hedge fund ADAR1 makes claims that the recent voting recommendation by Institutional Shareholder Services ('ISS') in connection with the election of directors at Keros' upcoming Annual Meeting constitutes an endorsement of ADAR1's aggressive campaign to oppose two highly qualified members of the Company's Board of Directors (the 'Board'). This notion is false and misleading. To be clear, the ISS recommendation is based on their standard voting guidelines for 'uncontested' director elections and was not reviewed by its special situations team that typically evaluates these types of campaigns. And unlike Glass Lewis, the report does not address any of ADAR1's misleading allegations or arguments. ADAR1's aggressive campaign to oppose two of the Board's highly qualified directors demonstrates a troubling disregard for Board diversity and critical expertise at a pivotal time for the Company. The Keros Board comprises nine directors, all of whom are independent except for the Company's CEO. This includes four representatives of Keros stockholders, two of whom are representatives of Pontifax, the Company's second largest stockholder. Collectively, the Board represents diverse perspectives and brings significant experience across the biotechnology industry, including drug development and commercialization, capital allocation, M&A and business development. In short, Keros has the right Board to oversee the ongoing strategic review process to maximize stockholder value and execute on the ultimate outcome of that process. The Board remains focused on successfully completing the strategic alternatives review process, which remains ongoing. We have always made, and will continue to make, decisions that we believe are in the best interests of the Company and ALL stockholders We strongly urge you to vote 'FOR' each of Keros' three director nominees, Mary Ann Gray, Ph.D., Ran Nussbaum and Alpna Seth, Ph.D. YOUR VOTE IS IMPORTANT, NO MATTER HOW MANY SHARES YOU MAY VOTE BY TELEPHONE, THE INTERNET OR MAIL BY FOLLOWING THE INSTRUCTIONS ON THE PROXY CARD. WE URGE YOU TO VOTE TODAY!If you have any questions or require any assistance with voting your shares, please contact: 7 Penn PlazaNew York, New York 10001Toll-Free: 1-800-322-2885Or Email: proxy@ Goldman Sachs & Co. LLC is serving as Keros' financial advisor, and Cooley LLP is serving as legal counsel. About Keros Therapeutics, is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. Keros is a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including blood, bone, skeletal muscle, adipose and heart tissue. By leveraging this understanding, Keros has discovered and is developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. One of Keros' product candidates, cibotercept (KER-012), is being developed for the treatment of pulmonary arterial hypertension and for the treatment of cardiovascular disorders. Keros' second product candidate, KER-065, is being developed for the treatment of neuromuscular diseases. Keros' most advanced product candidate, elritercept (KER-050), is being developed for the treatment of cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and in patients with myelofibrosis. Cautionary Note Regarding Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as 'anticipates,' 'believes,' 'continue,' 'expects,' 'enable,' 'potential' and 'will' or similar expressions are intended to identify forward-looking statements. Examples of these forward-looking statements include statements concerning the Annual Meeting and our director nominees, and the intended benefits of our classified Board structure. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: whether the objectives of the strategic alternative review process will be achieved; the terms, structure, benefits and costs of any strategic transaction; the timing of any transaction and whether any transaction will be consummated at all; the risk that the strategic alternatives review and its announcement could have an adverse effect on the ability of the Company to retain and hire key personnel and maintain relationships with partners, suppliers, employees, stockholders and other business relationships and on its operating results and business generally; the risk the strategic alternatives review could divert the attention and time of the Company's management; the risk of any unexpected costs or expenses resulting from the review; the risk of any litigation relating to the review; Keros' limited operating history and historical losses; Keros' ability to raise additional funding to complete the development and any commercialization of its product candidates; Keros' dependence on the success of its product candidates, cibotercept, KER-065 and elritercept; that Keros may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; the risk that circumstances surrounding or leading up to our 2025 Annual Meeting may change; Keros' ability to obtain, maintain and protect its intellectual property; and Keros' dependence on third parties in connection with manufacturing, clinical trials and preclinical studies. These and other risks are described more fully in Keros' filings with the Securities and Exchange Commission (the 'SEC'), including the 'Risk Factors' section of the Company's Quarterly Report on Form 10-Q, filed with the SEC on May 6, 2025, and its other documents subsequently filed with or furnished to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, Keros undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Important Additional Information and Where to Find It On April 23, 2025, the Company filed a definitive proxy statement on Schedule 14A (the "Proxy Statement") and form of accompanying proxy card with the SEC in connection with its 2025 Annual Meeting and its solicitation of proxies for the Company's director nominees and for other matters to be voted on. The Company may also file other relevant documents with the SEC regarding its solicitation of proxies for the 2025 Annual Meeting. This communication is not a substitute for any proxy statement or other document that the Company has filed or may file with the SEC in connection with any solicitation by the Company. STOCKHOLDERS OF THE COMPANY ARE STRONGLY ENCOURAGED TO READ THE PROXY STATEMENT AND OTHER RELEVANT DOCUMENTS FILED WITH, OR FURNISHED TO, THE SEC CAREFULLY AND IN THEIR ENTIRETY AS THEY CONTAIN IMPORTANT INFORMATION. Stockholders may obtain a copy of the Proxy Statement and any amendments or supplements to the Proxy Statement and any other relevant documents filed by the Company with the SEC at no charge at the SEC's website at Copies will also be available at no charge at the Company's website at Certain Information Regarding Participants This communication is neither a solicitation of a proxy or consent nor a substitute for any proxy statement or other filings that may be made with the SEC. The Company, its directors, its director nominees and certain of its executive officers and employees may be deemed to be participants in the solicitation of proxies for the 2025 Annual Meeting. Information regarding the names of such persons and their respective direct or indirect interests in the Company, by securities holdings or otherwise, is available in the Proxy Statement, which was filed with the SEC on April 23, 2025, including in the sections captioned "Compensation Discussion and Analysis," "Executive Compensation," "Non-Employee Director Compensation," "Transactions with Related Persons and Indemnification" and "Security Ownership of Certain Beneficial Owners and Management." To the extent that the Company's directors and executive officers have acquired or disposed of securities holdings since the applicable "as of" date disclosed in the Proxy Statement, such transactions have been or will be reflected on Statements of Changes in Ownership of Securities on Form 4 or Initial Statements of Beneficial Ownership of Securities on Form 3 filed with the SEC. These documents are or will be available free of charge at the SEC's website at Contacts Investor Contact:Justin Frantzjfrantz@ Media Contact:Mahmoud Siddig / Adam Pollack / Viveca TressJoele Frank, Wilkinson Brimmer Katcher(212) 355-4449 __________________1 Permission to obtain quotes was neither sought nor obtained. A photo accompanying this announcement is available at in to access your portfolio
Yahoo
10-04-2025
- Business
- Yahoo
Keros Therapeutics considers sale amid investor pressure
Keros Therapeutics' board of directors has authorised a 'poison pill defence'— in response to increasing investor interest in 'influencing the company's control'. The move comes after certain investors – including one individual holding 11.2% of Keros's outstanding common stock as of 6 April 2025 – expressed a desire to shape the company's strategic decisions. US-based Keros stated that the limited-duration stockholder rights plan is designed to protect the integrity of its ongoing strategic review process, which could include the potential sale of the company. As a result of the announcement, Keros's shares jumped by 13%, reaching $11.67 per share at market open. The company confirmed it has initiated a process to evaluate strategic alternatives and plans to provide updates on the process within 60 days of the 10 April announcement. This update follows a series of challenges faced by Keros related to its cibotercept clinical programme for pulmonary arterial hypertension (PAH). In December 2024, Keros halted higher-dose cohorts from the Phase II TROPOS study (NCT05975905) after a safety review revealed concerning adverse events, including fluid buildup around the heart – a development that saw the company's shares plunge by more than 77%. Keros suspended the two higher-dose groups and eventually ended the study in January 2025, citing 'the ongoing safety review due to new observations of pericardial effusion adverse events'. The candidate was positioned as a rival to MSD's PAH drug Winrevair (sotatercept). The US Food and Drug Administration (FDA) approved Winrevair in March 2024 and it is projected to reach blockbuster status, generating up to $6.4bn in global sales by 2030, as per GlobalData, the parent company of Pharmaceutical Technology. Keros's lead candidate is a TGF-beta inhibitor dubbed elritercept. The candidate is being investigated in the ongoing Phase III RENEW study (NCT06499285), targeting transfusion-dependent anaemia in very low, low or intermediate-risk myelodysplastic syndrome (MDS) patients. In December 2024, Takeda inked a deal worth up to $1.3bn with Keros to further develop, manufacture and commercialise elritercept worldwide outside of mainland China, Hong Kong and Macau. According to GlobalData's Pharma Intelligence Center, elritercept is projected to generate up to $425m in 2030, if approved. Keros is also advancing its pipeline with KER-065, a candidate for Duchenne muscular dystrophy (DMD), which has shown positive early-stage results. The company announced in March 2025 that KER-065 was well tolerated in Phase I trials, with evidence of activin inhibition across 'tissues of interest'. Following this announcement, Keros said it plans to engage with regulatory authorities in Q3 2025, with a Phase II trial for DMD expected to begin in Q1 2026, pending regulatory feedback. "Keros Therapeutics considers sale amid investor pressure" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
10-04-2025
- Business
- Yahoo
Keros Therapeutics Announces Review of Strategic Alternatives
Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process LEXINGTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ('Keros' or the 'Company') (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ('TGF-ß') family of proteins, today announced that its Board of Directors (the 'Board') has determined to initiate a formal review process to evaluate strategic alternatives to maximize stockholder value for the Company. In connection with this determination, the Board has authorized the formation of a committee, consisting of independent and disinterested directors, to oversee the process (the 'Strategic Committee') and make a recommendation to the full Board. The Strategic Committee, with the assistance of outside financial and legal advisors, intends to consider a comprehensive range of strategic alternatives, including but not limited to a sale of the company or other business combination transaction, continued investment in the Company's pipeline, and/or return of excess capital to stockholders. 'Consistent with our commitment to taking action to enhance stockholder value, Keros' Board determined to undertake a review of all strategic alternatives available to the Company,' said Jean-Jacques Bienaimé, Lead Independent Director. 'During the pendency of the strategic review process, we remain focused on the execution of our strategy.' There can be no assurance that this process will result in the Company pursuing a transaction or any other strategic outcome. There is no deadline or definitive timetable set for completion of the strategic alternatives review process. Keros intends to provide a preliminary update regarding the status of the process within 60 days of this announcement. Otherwise, Keros does not intend to disclose developments related to the process unless and until it determines that further disclosure is appropriate or necessary. Adoption of Stockholder Rights Plan The Company also announced that the Board has adopted a limited-duration stockholder rights plan (the 'Rights Plan'), effective immediately. The Board adopted the Rights Plan in response to significant and rapid accumulations of the Company's common stock by a number of investors who have indicated a desire to influence the control of Keros, including an individual investor which has informed the Company that it holds 11.2% of Keros' outstanding common stock as of April 6, 2025. The Rights Plan is intended to protect the interests of the Company and its stockholders, help ensure that all interested parties have the opportunity to participate fairly in the strategic review process and to provide the Board time to make informed decisions. The Rights Plan will reduce the likelihood that any entity, person or group gains control of Keros through open-market accumulation without paying all stockholders an appropriate control premium. The Rights Plan does not preclude the Board from engaging with parties or considering proposals or other strategic alternatives that it believes recognize the full value of the Company and are in the best interests of Keros and all stockholders. The Rights Plan, which is similar to other plans adopted by publicly held companies, does not contain any dead-hand, slow-hand, no-hand or similar feature that limits the ability of a future Board to redeem the rights. In connection with the adoption of the Rights Plan, the Board declared a dividend of one preferred share purchase right for each outstanding share of the Company's common stock as of the close of business on April 24, 2025, the record date. Under the Rights Plan, the rights will become exercisable if an entity, person or group acquires beneficial ownership of 10% or more (15% in the case of passive institutional investors) of Keros' outstanding common stock in a transaction not approved by the Board. In the event that the rights become exercisable due to the ownership threshold being crossed, each right will entitle its holder (other than the person, entity or group triggering the Rights Plan, whose rights will become void and will not be exercisable) to purchase additional shares of common stock having a then-current market value of twice the exercise price of the rights. Any stockholders with beneficial ownership of the Company's outstanding common stock at or above the applicable threshold prior to this announcement are grandfathered at their current ownership levels but are not permitted to increase their ownership without triggering the Rights Plan. In addition, the Rights Plan has customary flip-over and exchange features. Subject to the terms of the Rights Plan, the rights will expire on April 9, 2026 unless the rights are earlier redeemed or exchanged by Keros. Additional information regarding the Rights Plan will be contained in a Form 8-K to be filed by Keros with the U.S. Securities and Exchange Commission. Goldman Sachs & Co. LLC is serving as Keros' financial advisor, and Cooley LLP is serving as legal counsel. About Keros Therapeutics, Inc. Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. Keros is a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including blood, bone, skeletal muscle, adipose and heart tissue. By leveraging this understanding, Keros has discovered and is developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. One of Keros' product candidates, cibotercept (KER-012), is being developed for the treatment of pulmonary arterial hypertension and for the treatment of cardiovascular disorders. Keros' second product candidate, KER-065, is being developed for the treatment of neuromuscular diseases. Keros' most advanced product candidate, elritercept (KER-050), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and in patients with myelofibrosis. Cautionary Note Regarding Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as 'anticipates,' 'believes,' 'continue,' 'expects,' 'enable,' 'potential' and 'will' or similar expressions are intended to identify forward-looking statements. Examples of these forward-looking statements include statements concerning the intended benefits of the strategic review process and the adoption of the Rights Plan. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: whether the objectives of the strategic alternative review process will be achieved; the terms, structure, benefits and costs of any strategic transaction; the timing of any transaction and whether any transaction will be consummated at all; the risk that the strategic alternatives review and its announcement could have an adverse effect on the ability of the Company to retain and hire key personnel and maintain relationships with partners, suppliers, employees, shareholders and other business relationships and on its operating results and business generally; the risk the strategic alternatives review could divert the attention and time of the Company's management; the risk of any unexpected costs or expenses resulting from the review; the risk of any litigation relating to the review; Keros' limited operating history and historical losses; Keros' ability to raise additional funding to complete the development and any commercialization of its product candidates; Keros' dependence on the success of its product candidates, cibotercept, KER-065 and elritercept; that Keros may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; Keros' ability to obtain, maintain and protect its intellectual property; and Keros' dependence on third parties in connection with manufacturing, clinical trials and preclinical studies. These and other risks are described more fully in Keros' filings with the Securities and Exchange Commission ('SEC'), including the 'Risk Factors' section of the Company's Annual Report on Form 10-K, filed with the SEC on February 26, 2025, and its other documents subsequently filed with or furnished to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, Keros undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Contacts Investor Contact:Justin Frantzjfrantz@ Media Contact:Mahmoud Siddig / Adam Pollack / Viveca TressJoele Frank, Wilkinson Brimmer Katcher(212) 355-4449Sign in to access your portfolio
